These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 2250565

  • 1. Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers.
    Scheinin M, Koulu M, Karhuvaara S, Zimmer RH.
    Life Sci; 1990; 47(16):1491-9. PubMed ID: 2250565
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
    Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykkö K, Vuorinen J, Zimmer RH.
    Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
    [Abstract] [Full Text] [Related]

  • 3. Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.
    Scheinin M, Koulu M, Vakkuri O, Vuorinen J, Zimmer RH.
    Prog Neuropsychopharmacol Biol Psychiatry; 1990 Feb; 14(1):73-82. PubMed ID: 2300680
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE.
    J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Moclobemide effects on prolactin plasma levels in healthy individuals: the hormonal increase induced by a single dose is maintained during a 4-week period of drug intake.
    Juruena MF, Pires ML, Calil HM.
    Int Clin Psychopharmacol; 1997 Nov; 12(6):317-21. PubMed ID: 9547133
    [Abstract] [Full Text] [Related]

  • 14. Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men.
    Steiger A, Benkert O, Holsboer F.
    Neuropsychobiology; 1994 Nov; 30(2-3):101-5. PubMed ID: 7800155
    [Abstract] [Full Text] [Related]

  • 15. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography.
    Bergström M, Westerberg G, Németh G, Traut M, Gross G, Greger G, Müller-Peltzer H, Safer A, Eckernäs SA, Grahnér A, Långström B.
    Eur J Clin Pharmacol; 1997 Nov; 52(2):121-8. PubMed ID: 9174681
    [Abstract] [Full Text] [Related]

  • 16. Biochemistry and pharmacology of moclobemide, a prototype RIMA.
    Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M.
    Psychopharmacology (Berl); 1992 Nov; 106 Suppl():S6-14. PubMed ID: 1546143
    [Abstract] [Full Text] [Related]

  • 17. Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of alpha 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers.
    Scheinin M, Karhuvaara S, Ojala-Karlsson P, Kallio A, Koulu M.
    Life Sci; 1991 Nov; 49(1):75-84. PubMed ID: 1646924
    [Abstract] [Full Text] [Related]

  • 18. Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients.
    Gasic S, Korn A, Eichler HG, Oberhummer I, Zapotoczky HG.
    Eur J Clin Pharmacol; 1983 Nov; 25(2):173-7. PubMed ID: 6628500
    [Abstract] [Full Text] [Related]

  • 19. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
    Da Prada M, Kettler R, Keller HH, Burkard WP, Haefely WE.
    J Neural Transm Suppl; 1989 Nov; 28():5-20. PubMed ID: 2677242
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.